Get the Stockscreener App
0.2143
6.95%
-0.016
After Hours:
.21
-0.0043
-2.01%
Theriva Biologics Inc stock is traded at $0.2143, with a volume of 3.86M.
It is down -6.95% in the last 24 hours and down -35.65% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.2303
Open:
$0.2344
24h Volume:
3.86M
Relative Volume:
0.28
Market Cap:
$2.06M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.1847
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
-22.07%
1M Performance:
-35.65%
6M Performance:
-50.87%
1Y Performance:
-82.99%
1-Day Range:
$0.201
$0.2348
1-Week Range:
$0.201
$0.2808
52-Week Range:
$0.201
$2.08
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.2143 | 7.77M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Theriva Biologics Inc Stock (TOVX) Latest News
How Theriva Biologics Inc. (SFY0) stock reacts to new regulationsJuly 2025 Chart Watch & Risk Controlled Daily Trade Plans - newser.com
How Theriva Biologics Inc. stock responds to policy changes2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
Will Theriva Biologics Inc. stock top growth indexes2025 Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Is Theriva Biologics Inc. (SFY0) stock a top pick for value investors - newser.com
Is Theriva Biologics Inc. (SFY0) stock overpriced at current multiplesJuly 2025 Decliners & Stepwise Swing Trade Plans - newser.com
Can Theriva Biologics Inc. stock deliver consistent EPS growth2025 Top Gainers & Technical Pattern Based Signals - newser.com
Will Theriva Biologics Inc. stock outperform benchmarksJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Will Theriva Biologics Inc. stock maintain strong growthPortfolio Return Summary & Safe Entry Momentum Tips - newser.com
How Theriva Biologics Inc. stock reacts to monetary easingChart Signals & High Conviction Buy Zone Picks - newser.com
Can Theriva Biologics Inc. recover in the next quarterJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
How Theriva Biologics Inc. (SFY0) stock responds to bond marketJuly 2025 Analyst Calls & Weekly High Momentum Picks - newser.com
Trend analysis for Theriva Biologics Inc. this weekMarket Risk Analysis & Weekly High Return Opportunities - newser.com
Why Theriva Biologics Inc. stock gets analyst attentionRate Hike & Daily Stock Trend Reports - newser.com
Can Theriva Biologics Inc. stock survive global slowdownJuly 2025 Weekly Recap & Fast Exit/Entry Strategy Plans - newser.com
Can Theriva Biologics Inc. (SFY0) stock attract analyst upgradesDay Trade & Capital Protection Trade Alerts - newser.com
How Theriva Biologics Inc. stock reacts to job market dataQuarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
How Theriva Biologics Inc. (SFY0) stock reacts to Fed tighteningRecession Risk & Weekly High Potential Stock Alerts - newser.com
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.43%
Cap:
|
Volume (24h):